Table 1.
Baseline Patient and Tumor Characteristics (n=404)
| 03–30 (N=90) | 05–181 (N=314) | All patients (N=404) | P-Value* | ||
|---|---|---|---|---|---|
|
| |||||
| Age | mean +/− SD | 56.83 +/− 12.33 | 56.48 +/− 11.14 | 56.56 +/− 11.40 | 0.80 |
|
| |||||
| Tumor size (mm) | mean +/− SD | 13.64 +/− 12.09 | 12.76 +/− 13.58 | 12.96 +/− 7.41 | 0.32 |
|
| |||||
| Stage | I | 67 (74%) | 223 (71%) | 290 (72%) | 0.51 |
| IIA | 19 (21%) | 82 (26%) | 101 (25%) | ||
| IIB | 4 (4%) | 9 (3%) | 13 (3%) | ||
|
| |||||
| Tumor Stage | T1 | 77 (86%) | 260 (83%) | 337 (83%) | 0.54 |
| T2 | 13 (14%) | 54 (17%) | 67 (17%) | ||
|
| |||||
| Histology | Invasive Ductal | 72 (80%) | 265 (84%) | 337 (83%) | 0.57 |
| Invasive Lobular | 9 (10%) | 27 (9%) | 36 (9%) | ||
| Other | 9 (10%) | 22 (7%) | 31 (8%) | ||
|
| |||||
| Nodal Status | Negative | 75 (83%) | 267 (85%) | 342 (85%) | 0.69 |
| Positive | 15 (17%) | 47 (15%) | 62 (15%) | ||
|
| |||||
| Tumor estrogen receptor status | Negative | 15 (17%) | 57 (18%) | 72 (18%) | 0.75 |
| Positive | 75 (83%) | 257 (82%) | 332 (82%) | ||
|
| |||||
| Tumor progesterone receptor status | Negative | 36 (40%) | 123 (39%) | 159 (39%) | 0.89 |
| Positive | 54 (60%) | 191 (61%) | 245 (61%) | ||
|
| |||||
| Tumor Her2/Neu Status | Negative | 85 (94%) | 273 (90%) | 358 (89%) | 0.18 |
| Positive | 5 (6%) | 31 (10%) | 36 (9%) | ||
| Not Performed | 10 | 10 (2%) | |||
|
| |||||
| Breast Laterality | Left | 50 (56%) | 157 (50%) | 207 (51%) | 0.35 |
| Right | 40 (44%) | 157 (50%) | 197 (49%) | ||
|
| |||||
| Treatment position, based on optimal sparing of OAR | Prone | 90 (100%) | 283 (90%) | 373 (92%) | 0.002 |
| Supine | 0 | 31 (10%) | 31 (8%) | ||
|
| |||||
| Chemotherapy | Yes | 30 (33%) | 118 (38%) | 148 (37%) | 0.46 |
| No | 60 (67%) | 196 (62%) | 256 (63%) | ||
|
| |||||
| Antihormonal Therapy | Yes | 41 (46%) | 118 (38%) | 159 (39%) | 0.17 |
| No | 49 (54%) | 196 (62%) | 245 (61%) | ||
*
2-sample t-tests (2-sided) for continuous variables; chi-square tests for categorical variables.